Abstract
Most of the drugs available to treat type 2 diabetes mellitus (T2DM) act either in the pancreas by increasing insulin secretion or in tissues such as the liver or muscle by improving insulin sensitivity. However, recent studies have shown that the brain also plays a critical role in the regulation of glucose homeostasis. For example, central leptin administration reduces hyperglycemia and improves the survival of mice with type 1 diabetes mellitus (T1DM). In addition, several pieces of evidence show that the brain can control the insulin sensitivity in different tissues and the pancreatic secretion of insulin and glucagon. Therefore, the brain emerges as a promising new target of drugs aiming to treat both T1DM and T2DM. An exciting finding is that there is a partial overlap between neuronal populations that regulate energy balance and glucose homeostasis. Therefore, obesity and T2DM may have similar origins that are related to dysfunctions in the central nervous system. Likewise, future drugs that target the brain to treat T2DM may have beneficial effects in reducing body weight, and vice versa. In this review, the recent data showing how the brain is able to have an important regulatory effect over blood glucose levels as well as the possible neuronal circuitries involved in the control of glucose homeostasis will be summarized. The opportunities and challenges of using synthetic drugs or natural compounds that act in the central nervous system to treat diabetes mellitus will also be discussed.
Keywords: brain, drugs, hypothalamus, insulin, insulin resistance, leptin, diabetes mellitus (T2DM), hyperglycemia, glucose homeostasis, synthetic drugs, tissues.
Current Topics in Medicinal Chemistry
Title:The Central Nervous System as a Promising Target to Treat Diabetes Mellitus
Volume: 12 Issue: 19
Author(s): Jose Donato Jr.
Affiliation:
Keywords: brain, drugs, hypothalamus, insulin, insulin resistance, leptin, diabetes mellitus (T2DM), hyperglycemia, glucose homeostasis, synthetic drugs, tissues.
Abstract: Most of the drugs available to treat type 2 diabetes mellitus (T2DM) act either in the pancreas by increasing insulin secretion or in tissues such as the liver or muscle by improving insulin sensitivity. However, recent studies have shown that the brain also plays a critical role in the regulation of glucose homeostasis. For example, central leptin administration reduces hyperglycemia and improves the survival of mice with type 1 diabetes mellitus (T1DM). In addition, several pieces of evidence show that the brain can control the insulin sensitivity in different tissues and the pancreatic secretion of insulin and glucagon. Therefore, the brain emerges as a promising new target of drugs aiming to treat both T1DM and T2DM. An exciting finding is that there is a partial overlap between neuronal populations that regulate energy balance and glucose homeostasis. Therefore, obesity and T2DM may have similar origins that are related to dysfunctions in the central nervous system. Likewise, future drugs that target the brain to treat T2DM may have beneficial effects in reducing body weight, and vice versa. In this review, the recent data showing how the brain is able to have an important regulatory effect over blood glucose levels as well as the possible neuronal circuitries involved in the control of glucose homeostasis will be summarized. The opportunities and challenges of using synthetic drugs or natural compounds that act in the central nervous system to treat diabetes mellitus will also be discussed.
Export Options
About this article
Cite this article as:
Donato Jr. Jose, The Central Nervous System as a Promising Target to Treat Diabetes Mellitus, Current Topics in Medicinal Chemistry 2012; 12 (19) . https://dx.doi.org/10.2174/1568026611212190005
DOI https://dx.doi.org/10.2174/1568026611212190005 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inappropriate Medication Use and Cost Comparison Analysis of Proton Pump Inhibitors: Evidence from an Indian Tertiary Care Facility
Current Drug Safety Nocturia in Obstructive Sleep Apnea-Hypopnea Syndrome: An Underappreciated Symptom
Current Respiratory Medicine Reviews Epigenetic Modifications Associated with the Pathogenesis of Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Investigating Mitochondrial Dysfunction to Increase Drug Safety in the Pharmaceutical Industry
Current Drug Targets The GSTM1 and GSTT1 Null Genotypes Increase the Risk for Type 2 Diabetes Mellitus and the Subsequent Development of Diabetic Complications: A Meta-analysis
Current Diabetes Reviews Cardiometabolic Risk Related to the Association of hypertriglyceridemia-Low HDLc
Current Pharmaceutical Design Cocoa Polyphenols: Evidence from Epidemiological Studies
Current Pharmaceutical Design Development of Insulin Resistance During Aging: Involvement of Central Processes and Role of Adipokines
Current Protein & Peptide Science Statins and epilepsy: preclinical studies, clinical trials and statin-anticonvulsant drug interactions
Current Drug Targets Systematic Review of the Role of Microparticles in Systemic Sclerosis
Current Rheumatology Reviews The Role of Mediterranean Diet, CoQ10 and Conjugated-Melatonin in Osteoporosis Primary Prevention and Therapy
Current Nutrition & Food Science An Integrated and Disease-Oriented Growth Factor-Regulated Signal Transduction Network
Current Molecular Medicine 25 Hydroxyvitamin D Levels are Negatively and Independently Associated with Fat Mass in a Cohort of Healthy Overweight and Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Propranolol Safety Profile in Children
Current Drug Safety Systemic Vasculitis: An Epidemiological Perspective
Current Immunology Reviews (Discontinued) The Potential of Microalgae for the Production of Bioactive Molecules of Pharmaceutical Interest
Current Pharmaceutical Biotechnology Antiplatelet and Antileukocyte Effects of Cardiovascular,Immunomodulatory and Chemotherapeutic Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Complications of Anti-Vascular Endothelial Growth Factor Drugs
Current Drug Therapy Periodontal Disease and Potential Association with Systemic Diseases and Conditions (Mini-review)
Applied Clinical Research, Clinical Trials and Regulatory Affairs Endothelial Dysfunction and Platelet Hyperaggregation in Type 2 Diabetes Mellitus: The Era of Novel Anti-diabetic Agents
Current Medicinal Chemistry